Tergus Pharma Hires Top Manufacturing Executive

SAN FRANCISCO, CA--(Marketwired - Feb 10, 2016) - In a move that will further cement Tergus Pharma's (www.terguspharma.com) position as the industry leader in topical clinical supply manufacturing, the company has hired Ashik Pavagadhi as Head of Manufacturing Operations. Pavagadhi will take on the leadership of all aspects of clinical supply manufacturing of topical pharmaceuticals, ensuring client success and smoothing the way for later scale up and tech transfer.

Tergus is the industry leader in topical pharmaceutical development, skin biology & IVRT testing and Phase I - III cGMP clinical supply manufacturing. Mr. Pavagadhi has more than 18 years of experience in all aspects of successful pharmaceutical manufacturing.

"We are pleased that Ashik Pavagadhi has joined Tergus as Head of Manufacturing Operatins," said Vijendra Nalamothu, PhD, CEO and co-founder of Tergus. "He has an excellent track record and deep experience, which will help us continue our commitment to manufacturing excellence."

Mr. Pavagadhi holds an MBA from the University of Athabasca in Canada and a bachelor of science degree from the University of Manitoba, Canada in chemistry. His career includes manufacturing operations leadership positions at Heel, Inc., Chiron Corporation and Stryker Biotech. He acted as a manufacturing operations consultant to a number of leading pharmaceutical companies.

The hiring of Mr. Pavagadhi further solidifies Tergus's position as the industry leader in topical pharmaceutical clinical supply manufacturing. The company's capabilities extend to complicated manufacturing projects, ensuring success for clients. Tergus has acted as a strategic resource for scale up and tech transfer.

The company has enjoyed strong growth for the past few years and has attracted top talent in topical formulation, development, testing, analysis and manufacturing. It continues to grow its footprint, recently expanding to a more than 28,000 square-foot facility that includes top-of-the-line R&D labs, GMP manufacturing suite and the largest capability in the industry for IVRT and skin permeation studies. Tergus pioneered QbD for topical pharmaceuticals and continues to innovate and develop strategies that result in greater success for its clients.

Tergus offers complete topical pharmaceutical consulting services, development, formulation, analytical R&D, In Vitro Release Testing (IVRT), skin biology and cGMP clinical supplies manufacturing. The company has capability to produce clinical supplies up to 150kg using their state of the art manufacturing equipment. The company's motto is "Think Topical, Think Tergus."

About Tergus

Tergus (www.terguspharma.com) is the market leader in full-service topical pharmaceutical research, development, testing, analysis and manufacturing. The company has more than 20 years in business located in a state-of-the-art laboratory facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality and results for clients from formulation through manufacturing. Tergus pioneered Quality by Design (QbD) protocols for semi-solid delivery forms and has the largest bank of In Vitro Release Testing (IVRT) Franz Diffusion cells. The company's motto is "Think Topical. Think Tergus."

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.